Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Nov 3, 2025
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
Read more at globenewswire.com
